Drug-Coated Balloon for Small Coronary Artery Disease in Patients With and Without High-Bleeding Risk in the BASKET-SMALL 2 Trial.

Publication

Drug-Coated Balloon for Small Coronary Artery Disease in Patients With and Without High-Bleeding Risk in the BASKET-SMALL 2 Trial.

Journal Paper/Review - Apr 12, 2022

Scheller Bruno, Rissanen Tuomas T, Farah Ahmed, Ohlow Marc-Alexander, Mangner Norman, Wöhrle Jochen, Möbius-Winkler Sven, Weilenmann Daniel, Leibundgut Gregor, Cuculi Florim, Gilgen Nicole, Coslovsky Michael, Mahfoud Felix, Jeger Raban V, BASKET-SMALL 2 Investigators

Citation

Scheller B, Rissanen T, Farah A, Ohlow M, Mangner N, Wöhrle J, Möbius-Winkler S, Weilenmann D, Leibundgut G, Cuculi F, Gilgen N, Coslovsky M, Mahfoud F, Jeger R, BASKET-SMALL 2 Investigators. Drug-Coated Balloon for Small Coronary Artery Disease in Patients With and Without High-Bleeding Risk in the BASKET-SMALL 2 Trial. Circ Cardiovasc Interv 2022; 15:e011569.

Type

Journal Paper/Review (English)

Journal

Circ Cardiovasc Interv 2022; 15

Publication Date

Apr 12, 2022

Issn Electronic

1941-7632

Pages

e011569

Brief description/objective

Patients at high-bleeding risk (HBR) undergoing percutaneous coronary intervention represent a challenging patient population. The use of drug-coated balloon (DCB) allows shorter duration of dual antiplatelet therapy compared with drug-eluting stents (DES) and reduces thrombotic risk due to the absence of a permanent implant. The present analysis aimed to investigate if the effect of DCB versus DES differed between patients with and without HBR treated with percutaneous coronary intervention in small coronary arteries.